Patient-Friendly Explanation
Inflammatory bowel disease, or IBD, is the name for Crohn’s disease and ulcerative colitis, where the lining of the gut stays inflamed. Flare-ups cause diarrhoea, pain and poor absorption of food, so weight often drops; steroid treatment and reduced activity can then push weight back up. Both directions matter, and neither should be ignored.
Clinical Definition
IBD is chronic relapsing-remitting inflammation of the gastrointestinal tract, with malabsorption, protein-losing enteropathy and raised energy requirements during active disease. Corticosteroid courses and repeated inflammation promote central adiposity, insulin resistance and loss of lean mass, and obesity now coexists in a substantial minority of patients. Obesity complicates biologic dosing, cross-sectional imaging and surgical planning, while active disease plus restrictive eating raises the risk of micronutrient deficiency and sarcopenia.
Why It Matters
Weight should be tracked alongside disease activity markers rather than treated as a separate problem, and steroid exposure should be planned with bone and metabolic health in mind. NuLifeCare Singapore reviews nutrition, medication and weight together so that neither the flare nor the weight gain is missed.